Piramal Pharma Ltd
NSE:PPLPHARMA
Gross Margin
Piramal Pharma Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
P
|
Piramal Pharma Ltd
NSE:PPLPHARMA
|
296.6B INR |
63%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
236.5B CHF |
73%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
177B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
81%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199.7B CHF |
75%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
74%
|
Piramal Pharma Ltd
Glance View
Piramal Pharma Ltd. has embarked on a remarkable journey that reflects the dynamic world of pharmaceuticals and healthcare. Emerging from the rich tapestry of the Piramal Group's diverse business ventures, it has carved out a distinctive place for itself in the global pharmaceutical landscape. The company primarily navigates through three major streams: Contract Development and Manufacturing Organization (CDMO), Critical Care, and Consumer Products. Its CDMO division is the backbone, providing end-to-end solutions spanning the entire drug lifecycle, from development through to commercial manufacturing. By offering tailored solutions to pharmaceutical companies globally, Piramal Pharma not only strengthens its revenue streams but also builds lasting partnerships with some of the world’s leading pharmaceutical innovators. Beyond the realm of CDMO, Piramal Pharma's Critical Care segment specializes in catering to the acute care sector, dealing especially with inhalation anesthesia and pain management solutions. This division operates globally, emphasizing a diligent supply chain that ensures these life-sustaining products reach hospitals and clinics around the world. Meanwhile, its Consumer Products business makes a concerted effort to touch lives in a different manner—through over-the-counter health solutions that meet everyday health concerns of countless individuals. Operating at this unique intersection where science meets humanity, Piramal Pharma not only thrives through product sales but also invests heavily in R&D, seeking out innovative ways to address evolving market needs and inch its way forward in the competitive pharmaceutical arena.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Piramal Pharma Ltd's most recent financial statements, the company has Gross Margin of 63.2%.
You don't have any saved screeners yet